HER2 protein overexpression – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:20:53 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png HER2 protein overexpression – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A Study of Zanidatamab for Patients with Previously Treated HER2-Expressing Solid Tumors https://clinicaltrials.eu/trial/a-study-of-zanidatamab-for-patients-with-previously-treated-her2-expressing-solid-tumors/ Thu, 30 Apr 2026 13:08:23 +0000 https://clinicaltrials.eu/trial/a-study-of-zanidatamab-for-patients-with-previously-treated-her2-expressing-solid-tumors/ This study is looking at patients who have solid tumors that show a protein called HER2 on their surface. These are cancers that have spread or grown in a way that cannot be removed by surgery, and previous treatments have not worked. The study will use a medicine called zanidatamab, which is also known by its code name JZP598. This medicine is given through a needle into a vein over a period of time, known as an infusion. The purpose of the study is to see how well zanidatamab works against these tumors and how safe it is for patients to use.

Patients in this study will receive zanidatamab on its own, without combining it with other cancer treatments. The medicine will be given regularly over a treatment period that can last up to 60 weeks. The doctors will check how the tumors respond to the treatment by doing regular scans and tests. Some patients in the study may have breast cancer or cancers of the stomach and food pipe area, and they may have received a specific type of HER2-targeted therapy before, which is a treatment that works against the HER2 protein. For other types of solid tumors, patients should not have had this type of treatment before.

During the study, doctors will monitor patients carefully to see if the treatment is working and to watch for any side effects. This includes checking heart function, blood tests to see how the liver and kidneys are working, and measuring the size of the tumors. Patients will also be asked about symptoms they experience using questionnaires. The study will look at how many patients see their tumors shrink, how long the treatment keeps working, and how long patients live. Blood samples will be taken to measure the amount of medicine in the body and to check if the body makes any reaction against the medicine.

]]> Study of BDC-1001 and Nivolumab for Patients with Advanced HER2-Positive Solid Tumors https://clinicaltrials.eu/trial/study-of-bdc-1001-and-nivolumab-for-patients-with-advanced-her2-positive-solid-tumors/ Wed, 29 Apr 2026 14:57:49 +0000 https://clinicaltrials.eu/trial/study-of-bdc-1001-and-nivolumab-for-patients-with-advanced-her2-positive-solid-tumors/ This clinical trial is focused on studying treatments for patients with advanced HER2-expressing solid tumors. These are types of cancer that have a protein called HER2 on their surface, which can make the cancer grow more quickly. The study is testing a new treatment called BDC-1001, both on its own and in combination with another medication called nivolumab, which is also known by its code names BMS936558 and ABP 206. Nivolumab is a type of drug that helps the immune system fight cancer.

The purpose of the study is to find out how safe and tolerable BDC-1001 is when used alone and when combined with nivolumab. The study will also look at how well these treatments work against the cancer. The study is divided into different parts. In the first part, patients will receive BDC-1001 alone to see how their bodies react to it. In the second part, patients will receive both BDC-1001 and nivolumab to see if the combination is safe and effective. Later parts of the study will focus on how well the treatments work in shrinking the tumors or stopping them from growing.

Participants in the study will receive the treatments through an infusion, which means the medication is given directly into the bloodstream through a vein. The study will monitor patients closely to check for any side effects and to see how the cancer responds to the treatment. The goal is to find the best dose of BDC-1001 that can be used safely and effectively, both on its own and with nivolumab, for treating advanced HER2-expressing solid tumors.

]]>